Reducing Polypharmacy and Fall Risk for Multi-Morbid Adults with Chronic Obstructive Pulmonary Disease

减少患有慢性阻塞性肺病的多种疾病成人的多重用药和跌倒风险

基本信息

批准号：
10688259
负责人：
Cara Lyn McDermott
金额：
$ 17.99万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10688259
关键词：
Academic Medical Centers Address Adult Award Behavior Therapy Behavioral trial Benzodiazepines Caregivers Caring Cessation of life Chronic Obstructive Pulmonary Disease Clinic Clinical Clinical Trials Clinical Trials Design Communication Communities Data Databases Dedications Drug Combinations Drug usage Emergency department visit Evaluation Evidence based intervention Family Caregiver Funding Future Goals Health Healthcare Hospitalization Hospitals Incidence Individual Injury Intervention Intervention Trial Interview Knowledge Learning Lung Managed Care Measures Medication Management Morbidity - disease rate Muscle relaxants National Heart, Lung, and Blood Institute Opioid Outcome Outpatients Oxygen Pain Participant Patient Care Patients Pharmaceutical Preparations Pharmacists Polypharmacy Population Primary Care Quality of life Questionnaires Recording of previous events Reporting Research Risk Risk Assessment Scientist Sleeplessness Source Statistical Methods Structure Symptoms Testing Therapeutic Training Treatment Efficacy Tricyclic Antidepressive Agents Tube Visit Withdrawal Work anxiety symptoms behavioral clinical trial career comparative efficacy cost effectiveness/implementation trial fall injury fall risk falls frailty functional status health care delivery high risk hypnotic implementation science improved individual patient innovation intervention participants medical specialties medication safety mortality novel patient oriented patient population patient safety pilot trial primary care clinic primary care provider primary outcome programs provider communication randomized trial safety net sedative shared decision making symptom treatment treatment as usual

项目摘要

Project summary Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the US and results in significant reduction in quality of life and functional status. Patients with COPD are 55 times more likely to fall than patients without COPD, putting these patients at high risk of fall-related injuries and further decrements in quality of life and health. This study will tackle the common and important problem of use of fall- risk increasing drugs (FRIDs) among patients with COPD. This will be achieved by implementing and evaluating a pharmacist-led deprescribing intervention to reduce FRIDs use among community-dwelling, multi- morbid adults with COPD. The central hypothesis of this proposal is that poor communication and limited shared decision making between prescribers, patients, and patient caregivers represent modifiable barriers to deprescribing. Once these barriers are addressed, prescribers, patients and caregivers will be amenable to informed deprescribing as part of this targeted intervention. In Specific Aim 1, I will use a national database to assess commonly used FRIDs among patients with COPD, identifying FRID types and combinations associated with the highest fall risk. In Specific Aim 2, I will interview patients with COPD, their family caregivers, and clinicians (primary care providers, pulmonologists, pharmacists) to elicit barriers, facilitators and key strategies to deprescribing FRIDs and enhancing shared decision making between clinicians and patients. In Specific Aim 3, I will conduct a pilot randomized trial, testing a pharmacist-led deprescribing intervention, adapted using findings from Specific Aims 1 and 2. I will evaluate the feasibility, acceptability and appropriateness of the intervention using semi-structured interviews and structured questionnaires. I will also explore the preliminary efficacy of the intervention compared to usual care for the primary outcome of FRID discontinuation. This pilot trial will provide preliminary data for a future R01-funded hybrid effectiveness- implementation trial. This research is innovative in that: 1) no prior study has evaluated an intervention to facilitate deprescribing FRIDs among patients with COPD; 2) this intervention includes family caregivers, who provide informal medication management to patients; and 3) this project uses a pulmonary clinic-based pharmacist as a conduit to improve communication and shared decision making among patients, caregivers and clinicians. My learning objectives are to learn a) advanced statistical methods to evaluate fall risk among patients with COPD, b) training on COPD therapeutics and fall risk assessment, c) behavioral intervention optimization, adaptation and assessment, and d) behavioral clinical trials design for future intervention trials. My long-term career goals are to evaluate and disseminate evidence-based interventions to improve medication management and healthcare delivery for multi-morbid adults with COPD.

项目概要慢性阻塞性肺疾病（COPD）是美国和美国发病率和死亡率的主要原因导致生活质量和功能状态显着下降。慢性阻塞性肺病 (COPD) 患者增加 55 倍比没有慢性阻塞性肺病的患者更有可能跌倒，使这些患者面临跌倒相关伤害的高风险，并且进一步生活质量和健康下降。这项研究将解决使用秋季的常见且重要的问题 COPD 患者的风险增加药物（FRID）。这将通过实施和实现评估药剂师主导的取消处方干预措施，以减少社区居住、多人群中 FRID 的使用患有慢性阻塞性肺病（COPD）的病态成年人。该提案的中心假设是沟通不畅和有限处方者、患者和患者护理人员之间的共同决策代表了可改变的障碍取消处方。一旦这些障碍得到解决，处方者、患者和护理人员将能够接受作为这一有针对性的干预措施的一部分，知情减少处方。在具体目标 1 中，我将使用国家数据库来评估 COPD 患者常用的 FRID，确定 FRID 类型和组合与最高的跌倒风险相关。在具体目标 2 中，我将采访 COPD 患者及其家人护理人员和临床医生（初级保健提供者、肺科医师、药剂师）来引发障碍、促进者以及取消 FRID 处方和加强临床医生和患者之间共同决策的关键策略患者。在具体目标 3 中，我将进行一项试点随机试验，测试药剂师主导的取消处方干预措施，根据具体目标 1 和 2 的调查结果进行调整。我将评估可行性、可接受性和使用半结构化访谈和结构化问卷进行干预的适当性。我也会探讨干预措施与常规护理相比对 FRID 主要结局的初步疗效停产。该试点试验将为未来 R01 资助的混合有效性提供初步数据 - 实施试点。这项研究的创新之处在于：1）之前没有研究评估过干预措施促进 COPD 患者取消 FRID 处方； 2) 这项干预措施包括家庭照顾者，他们为患者提供非正式的药物管理； 3) 该项目使用基于肺部诊所的药剂师作为改善患者、护理人员之间沟通和共同决策的渠道和临床医生。我的学习目标是学习 a) 先进的统计方法来评估跌倒风险慢性阻塞性肺病患者，b) 慢性阻塞性肺病治疗和跌倒风险评估培训，c) 行为干预优化、适应和评估，以及 d) 为未来干预试验设计行为临床试验。我的长期职业目标是评估和传播基于证据的干预措施，以改善患有慢性阻塞性肺病的多病成人的药物管理和医疗保健服务。